Asco 2021 – the exon 20 army lines up behind Rybrevant
A new lung cancer niche is a major focus of Asco, with China's Dizal perhaps boasting the most intriguing dataset.
www.evaluate.com
Amivantamab(Rybrevant, Janssen) : egfr & Met
https://en.wikipedia.org/wiki/Amivantamab : 2021.5 FDA 승인
https://blog.naver.com/kmalsh/222426565528
https://m.healthcaren.com/news/news_article_yong.jsp?mn_idx=365978
https://www.mdalert.com/article/targeted-therapy-for-nsclc-subgroup-1-1
Mobocertinib(Exkivity,Takeda Pharmaceuticals, Inc.) : irreversible kinase inhibitor, a first-in-class oral treatment,
https://en.wikipedia.org/wiki/Mobocertinib : 2021.9 FDA 승인
http://www.yakup.com/news/index.html?mode=view&nid=261293
BDTX-189 ( Black Diamond Therapeutics, Inc.): selective inhibitor of allosteric EGFR and HER2
Poziotinib (한미약품)
https://en.wikipedia.org/wiki/Poziotinib
https://www.selleckchem.com/products/poziotinib-hm781-36b.html
http://www.biospectator.com/view/news_view.php?varAtcId=14354
http://www.biospectator.com/view/news_view.php?varAtcId=14349
My Thoughts on Recently Approved Therapies for EGFR Exon 20 Insertion Mutation–Positive Advanced NSCLC
https://www.clinicaloptions.com/oncology/programs/2021/nsclc-egfr-ex20/clinicalthought/ct2/page-1
ClinicalThought - EGFR ex20ins+ NSCLC: Therapy - ClinicalThought - Targeting EGFR Exon 20 in NSCLC
Joshua Sabari, MD, discusses the clinical use of recently approved therapies for EGFR exon 20 insertion mutations in the management of advanced NSCLC, in this Clinical Care Options (CCO) commentary
www.clinicaloptions.com
'신약개발 소식, 해외 논문들' 카테고리의 다른 글
| '항암제 패러다임 바꾼다'...조직불문항암제 주목 (0) | 2021.10.22 |
|---|---|
| 일부 암 환자에게만 효능 보이는 면역항암제 한계 극복했다(나노입자) (0) | 2021.10.22 |
| AZ백신 기술로 ‘항암 백신’ 만든다 (0) | 2021.09.06 |
| 리보세라닙(RIVOCERANIB (APATINIB)) (0) | 2021.09.02 |
| KAIST·삼성서울병원, 암 조직 태워 제거 '소작 바늘' 상용화 (0) | 2021.09.02 |